FK 506 affects platelet aggregation in vitro.

[1]  P. Mcmaster,et al.  FK 506 in transplantation. , 1993, Transplantation Proceedings.

[2]  A. Oriente,et al.  Anti-inflammatory effect of FK-506 on human skin mast cells. , 1992, The Journal of investigative dermatology.

[3]  N. Perico,et al.  THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE , 1992, Transplantation.

[4]  A. Oriente,et al.  Characterization of the anti-inflammatory effect of FK-506 on human mast cells. , 1991, Journal of immunology.

[5]  A. E. Trezíse,et al.  FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. , 1991, Transplantation proceedings.

[6]  N. Sigal,et al.  FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. , 1991, Biochemical pharmacology.

[7]  G. Schultz,et al.  The superoxide-forming NADPH oxidase of phagocytes. An enzyme system regulated by multiple mechanisms. , 1991, Reviews of physiology, biochemistry and pharmacology.

[8]  C. Fisher,et al.  Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. , 1991, The Journal of surgical research.

[9]  S. Schreiber,et al.  Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Condorelli,et al.  FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. , 1991, Journal of immunology.

[11]  T. Starzl,et al.  FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION , 1989, The Lancet.

[12]  T. Starzl,et al.  Renal transplantation in baboons under FK 506. , 1989, Transplantation proceedings.

[13]  H. Shimada,et al.  Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. , 1989, Transplantation.

[14]  G. Remuzzi,et al.  Renal vascular and thrombotic effects of cyclosporine. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  T. Rimele,et al.  Interaction of neutrophils with vascular smooth muscle: identification of a neutrophil-derived relaxing factor. , 1988, The Journal of pharmacology and experimental therapeutics.

[16]  A. Grace,et al.  Cyclosporine A enhances platelet aggregation. , 1987, Kidney international.

[17]  P. Friend,et al.  FK-506 in experimental renal allografts. , 1987, Transplantation proceedings.

[18]  H. Sharma,et al.  Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. , 1985, American journal of surgery.

[19]  T. Lerut,et al.  THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS , 1985, The Lancet.

[20]  R. Griffiths,et al.  The effect of 6‐oxo‐prostaglandin E1 on human platelet aggregation in whole blood in‐vitro , 1985, The Journal of pharmacy and pharmacology.

[21]  J. Feehally,et al.  Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  T. C. Jones,et al.  Pathology of Laboratory Animals , 1978, Springer New York.